COMMUNIQUÉS West-GlobeNewswire

ImmuneSensor Therapeutics Receives Clearance from Australian Regulators to Initiate a First-in-Human Phase 1 Clinical Trial of cGAS inhibitor Drug Candidate, IMSB301

19/08/2024 - 14:00

Novel, oral IMSB301 is a potent cGAS inhibitor designed to block signaling through a central pathway that drives diverse inflammatory and autoimmune diseases Company expects to initiate its Phase 1 clinical trial in [...]

Assure Announces Further Extension of Exchange Offer Relating to its Convertible Notes

19/08/2024 - 14:00

DENVER, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (“Assure” or the “Company”) (OTC: IONM), today announced that it has extended the expiration date of its exchange offer (the “Offer”) relating to the [...]

Processa Pharmaceuticals Announces Positive Preclinical Data for NGC-Iri

19/08/2024 - 14:00

Delivers more cancer-killing SN-38 molecules to tumor than irinotecan and Onivyde ® Studies support potential benefit as an improved treatment with fewer side effects HANOVER, Md., Aug. 19, 2024 (GLOBE NEWSWIRE) -- [...]

Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

19/08/2024 - 14:00

Carlsbad, CA, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for [...]

Calibre Scientific Acquires Industrial Glassware, a U.S. Manufacturer and Provider of Laboratory Supplies and Consumables

19/08/2024 - 13:53

LOS ANGELES, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Calibre Scientific is pleased to announce the acquisition of Industrial Glassware (the “Company”), a U.S.-based manufacturer of caps, glass vials, glass and plastic bottles [...]

BridgeBio Launches MyAchonJourney, a New Resource for Families Navigating Achondroplasia

19/08/2024 - 13:30

PALO ALTO, Calif., Aug. 19, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases, and QED Therapeutics, the BridgeBio [...]

Kraig Biocraft Laboratories Successfully Completes Third Commercial Spider Silk Production Cycle

19/08/2024 - 13:05

ANN ARBOR, Mich., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), announces today that it has completed the third commercial spider silk production [...]

Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA

19/08/2024 - 13:00

PDUFA Target Action Date of February 1, 2025 ROCKVILLE, Md., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing [...]

Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer

19/08/2024 - 13:00

CAMBRIDGE, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of [...]

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

19/08/2024 - 13:00

Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2025 Initiation of the first clinical trial of APG777 and APG990 combination expected to commence in 2025 with the potential [...]

UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

17/08/2024 - 17:27

Following recent transactions and cost-cutting efforts, Sol-Gel’s cash runway is expected to extend into the first quarter of 2026 Ongoing Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with over 30 clinical [...]

Bavarian Nordic Provides Statement on Mpox Vaccine Supply and Collaboration with African and Global Stakeholders

17/08/2024 - 13:26

COPENHAGEN, Denmark, August 17, 2024 – Bavarian Nordic A/S (OMX: BAVA) provides an update on plans for securing supply of vaccines to tackle the current mpox outbreak that the Africa Centers for Disease Control and [...]

Cannara Biotech atteint sa part de marché nationale la plus élevée, soit 3,2 %, en juillet 2024 et annonce la tenue d’une webdiffusion pour les investisseurs le 20 août 2024

17/08/2024 - 02:25

MONTRÉAL, 16 août 2024 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (« Cannara » ou la « Société ») ( TSXV : LOVE ) ( OTCQB : LOVFF) ( FRA : 8CB0 ), un producteur verticalement intégré de cannabis de qualité supérieure et d [...]

Helius Medical Technologies, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

16/08/2024 - 23:00

NEWTOWN, Pa., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that, effective August [...]

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

16/08/2024 - 23:00

SAN CARLOS, Calif., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal [...]

Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards

16/08/2024 - 22:30

SARASOTA, Fla., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) ("the Company"), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, [...]

Alignment Healthcare Updates its Board of Directors

16/08/2024 - 22:30

ORANGE, Calif., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), today announced that Thomas (TJ) Carella and Jeffrey Margolis are stepping down as members of its Board of Directors, [...]

SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 million

16/08/2024 - 22:30

SciSparc will receive consideration in shares, and in addition may receive cash payments and fees if certain development milestones are met TEL AVIV, Israel, Aug. 16, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC [...]

ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics

16/08/2024 - 22:15

Special dividend estimated to be $1.59 per share Payment of special dividend conditioned upon ARCA stockholder approval of the Proposed Merger with Oruka WESTMINSTER, Colo., Aug. 16, 2024 (GLOBE NEWSWIRE) -- ARCA [...]